• Username (E-mail)
  • Password
Dow 21,141 1.6%  EStoxx50 3,390 2.1%  Nikkei 19,394 1.4%  EUR 1.0551 -0.2% 
Nasdaq 5,905 1.4%  FTSE100 7,383 1.6%  Yen 113.6540 0.7%  Oil 56.4 1.5% 
S&P500 2,398 1.4%  DAX 12,067 2.0%  GBP 1.2292 -0.7%  Gold 1,250 0.1% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

11/07/2016 08:43:28 AM
11/07/2016 08:43:28 AM UTC-0500

Vertex Pharma: ORKAMBI Study Meets Endpoint In Children With Cystic Fibrosis

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced the results of a Phase 3 study of ORKAMBI (lumacaftor/ivacaftor) in children with cystic fibrosis ages 6 through 11 who have two copies of the F508del mutation. The study met its primary endpoint of absolute change in lung clearance index (LCI2.5) through 24 weeks of treatment, demonstrating a statistically significant improvement in LCI2.5 among patients treated with ORKAMBI compared to placebo. In the study, ORKAMBI was well tolerated with safety data that were similar to data from the previous Phase 3 study.

Jeffrey Chodakewitz, Chief Medical Officer at Vertex, stated: "We are preparing to submit these important data to the EMA in the first half of 2017, and we look forward to bringing ORKAMBI to eligible children in Europe as soon as possible."

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
Vertex Pharmaceuticals Goldman Sachs Group Inc.
Vertex Pharmaceuticals RBC Capital Markets
Vertex Pharmaceuticals Credit Suisse Group
Vertex Pharmaceuticals Goldman Sachs Group Inc.
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Stock Market

News Ticker


  • News on Stocks
  • All News